{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:34:24Z","timestamp":1791041664591,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":798,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The guideline-directed medical therapy (GDMT) has been recommended for heart failure (HF) with reduced ejection fraction (HFrEF) based on the accumulating clinical evidence. However, it is difficult to implement all the trial-proven medications for every patient in the real world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A simple GDMT score was created, according to the combination of GDMT drugs (renin\u2013angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium\u2013glucose transporter 2 inhibitors) administration and their dosage (0\u20139 points). Its impact on the prognosis of HF patients was investigated. Admitted HF patients [HFrEF and HF with mildly reduced ejection fraction (HFmrEF), n = 1054] were retrospectively analysed (excluding those with in-hospital death and dialysis). A simple GDMT score \u22655, but not the number of medications, was significantly associated with a reduction of all-cause death, HF readmission, and composite outcome (HF readmission and all-cause death) (P &amp;lt; 0.001). Subgroup analysis showed that almost all groups with a simple GDMT score of 5 or higher had a better prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The developed simple GDMT score was associated with prognosis in HFrEF and HFmrEF patients. Even if all four drugs cannot be introduced for some reason, a regimen with a simple GDMT score \u22655 may lead to a prognosis in HF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14524","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T04:50:10Z","timestamp":1693975810000},"page":"3352-3363","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A Scoring Evaluation for the Practical Introduction of Guideline-Directed Medical Therapy in Heart Failure Patients"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-2123","authenticated-orcid":false,"given":"Ryuichi","family":"Matsukawa","sequence":"first","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihide","family":"Okahara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tokutome","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Itonaga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kisanuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Okabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohide","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Fukuoka Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"2026012113210343400_ehf214524-bib-0001","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113210343400_ehf214524-bib-0002","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113210343400_ehf214524-bib-0003","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113210343400_ehf214524-bib-0004","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: The fantastic four","volume":"42","author":"Johann","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113210343400_ehf214524-bib-0005","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2020.10.014","article-title":"Treatment of HF in an era of multiple therapies: Statement from the HF Collaboratory","volume":"9","author":"Bhatt","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0006","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0007","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026012113210343400_ehf214524-bib-0008","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J Card Fail"},{"key":"2026012113210343400_ehf214524-bib-0009","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026012113210343400_ehf214524-bib-0010","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0011","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012113210343400_ehf214524-bib-0012","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014Inertia, titration, and discontinuation: A multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0013","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: A secondary analysis of a randomized clinical trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012113210343400_ehf214524-bib-0014","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jchf.2020.10.002","article-title":"Standardized definitions for evaluation of heart failure therapies: Scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium","volume":"8","author":"Abraham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0015","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jchf.2020.08.016","article-title":"Putting the \u201coptimal\u201d in optimal medical therapy","volume":"9","author":"DeFilippis","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0016","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jchf.2022.05.001","article-title":"The Heart Failure Collaboratory medical therapy score: Quantifying the quality of goal-directed medical therapy","volume":"10","author":"Hong","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0017","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacc.2021.11.033","article-title":"Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week","volume":"79","author":"Fiuzat","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012113210343400_ehf214524-bib-0018","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: The Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N Engl J Med"},{"key":"2026012113210343400_ehf214524-bib-0019","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026012113210343400_ehf214524-bib-0020","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2022.03.009","article-title":"Effects of dapagliflozin according to the Heart Failure Collaboratory medical therapy score: Insights from DAPA-HF","volume":"10","author":"Butt","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0021","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009729","article-title":"A composite score summarizing use and dosing of evidence-based medical therapies in heart failure: A nationwide cohort study","volume":"0","author":"Johansen","year":"2023","journal-title":"Circ: Heart Failure"},{"key":"2026012113210343400_ehf214524-bib-0022","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026012113210343400_ehf214524-bib-0023","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113210343400_ehf214524-bib-0024","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012113210343400_ehf214524-bib-0025","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1253\/circj.CJ-20-0947","article-title":"Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF)","volume":"85","author":"Ide","year":"2021","journal-title":"Circ J"},{"key":"2026012113210343400_ehf214524-bib-0026","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cardfail.2019.04.004","article-title":"Prognostic value of BNP reduction during hospitalization in patients with acute heart failure","volume":"25","author":"Kagiyama","year":"2019","journal-title":"J Card Fail"},{"key":"2026012113210343400_ehf214524-bib-0027","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ahj.2007.01.041","article-title":"Repeated hospitalizations predict mortality in the community population with heart failure","volume":"154","author":"Setoguchi","year":"2007","journal-title":"Am Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/6\/3352\/64699315\/eschf_10_6_3352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/6\/3352\/64699315\/eschf_10_6_3352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:25:39Z","timestamp":1769019939000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/6\/3352\/8284380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,9,6]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14524","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,9,6]]},"assertion":[{"value":"2023-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}